stocks logo

KZIA Stock Price Prediction

Kazia Therapeutics Ltd
$
1.000
+0.005(+0.500%)

KZIA Similar Chart Price Prediction

The price of KZIA is predicted to go up 6.67%, based on the high correlation periods with PHI. The similarity of these two price pattern on the periods is 97.23%.

stocks logo

KZIA

Future prediction

Up: 6.67%

Sign Up to See Future Prediction
stocks logo

PHI

Up: 6.67%Similarity: 97.23%

KZIA Revenue Forecast

KZIA EPS Forecast

KZIA VS S&P500

Kazia Therapeutics Ltd
SPDR S&P 500

KZIA Analyst's Forecast

Jason McCarthy

Maxim Group

Strong Buy

2025-02-06

Price Target

$3

Upside

+129.01%

Maxim initiated coverage of Kazia Therapeutics with a Buy rating and $3 price target. The company's lead asset is paxalisib, a potent, oral, brain-penetrant small molecule inhibitor of PI3K and mTOR being developed as an adjuvant therapy to treat newly diagnosed unmethylated glioblastoma - GBM - multiforme, the analyst tells investors in a research note. Paxalisib has shown numerical overall survival benefits in two studies involving unmethylated GBM patients, and while the drug did not progress to the second stage after being evaluated in the Glioblastoma Adaptive Global Innovative Learning Environment platform trial, it demonstrated consistent overall survival benefits with a prior Phase 2 study, Maxim notes, adding that Kazia is on pace to initiate a Phase 3 trial for paxalisib in the second half of this year.